European Congress of Clinical Microbiology and Infectious Diseases: April 2013

May 2013
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p21
A table is presented which lists status of clinical trials performed by various companies including Pfizer Inc., Tetraphase Pharmaceuticals Inc., and by Trius Therapeutics Inc. elaborated upon during the 23rd European Congress of Clinical Microbiology and Infectious Diseases in April 2013.


Related Articles

  • Called Off.  // Pharmaceutical Executive;Oct2000, Vol. 20 Issue 10, p160 

    Reports that the Phase III trials of prinomastat, a matrix matalloprotease inhibitor, was discontinued by Pfizer. Reasons for the discontinuation of the trials; Details on other trials of prinomastat that are underway.

  • Trius' TR-701 Advances with $30M Series B.  // Bioworld Week;3/31/2008, Vol. 16 Issue 13, p2 

    The article reports that Trius Therapeutics Inc. has brought $30 million in its second venture to advance studies into Phase III with lead program TR-701, an oxazolidinone antibiotic. Phase I showed promising results with the trial testing against Pfizer's Zyvox, the only approved oxazolidinone...

  • Trius 'Establishes' Key Endpoints For its Tedizolid Phase III Trial.  // BioWorld Today;2/14/2013, Vol. 24 Issue 31, p2 

    The article reports on the results of the first pivotal Phase III study conducted by Trius Therapeutics Inc. on tedizolid phosphate and linezolid for acute bacterial skin and skin structure infections (ABSSSI), which were published in the "Journal of the American Medical Association" (JAMA).

  • ICAAC 2011.  // BioWorld Today;9/20/2011, Vol. 22 Issue 182, p9 

    The article focuses on the results presented by Trius Therapeutics Inc. at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) from a Phase II trial of antibiotic tedizolid phosphate.

  • Clinic Roundup.  // BioWorld Today;8/31/2010, Vol. 21 Issue 168, p9 

    This section offers news briefs related to clinical trials as of August 31, 2010, including one on the anti-anxiety compound of Bionomics Ltd., another on the Vacc-4x of Bionor Pharma ASA, and another on the Phase III study of torezolid from Trius Therapeutics Inc.

  • Trial on Trial. Silverman, Ed // Contract Pharma;2009, Vol. 11 Issue 7, p48 

    The article focuses on the implications of a judicial case of Pfizer Inc. on the pharmaceutical industry. Pfizer settled the civil and criminal charges for illegally testing its trovan antibiotic on children during a 1996 menningitis epidemic in Nigeria. This incident affected the entire...

  • Pfizer Pullout Sends NicOx Shares Down.  // BioWorld Today;5/7/2008, Vol. 19 Issue 89, p2 

    The article reports on the decline in the share price of French biotechnology company NicOx SA following the withdrawal of Pfizer Inc. from the company's Phase II trial in glaucoma and ocular hypertension in May 2008. Details of the clinical trial is given. Reportedly, the share price of NicOx...

  • Stomach Cancer Update.  // PharmaWatch: Cancer;Mar2006, Vol. 5 Issue 3, p15 

    The article reports on developments about drugs for treating stomach cancer. GenVec Inc.'s investigational drug TNFerade has showed positive results from a phase II clinical trial. Pfizer Inc.'s Sutent has been approved by the U.S. Food and Drug Administration for treating gastrointestinal...

  • Cholesterol, Cholesterol-Lowering Agents/Statins, and Urologic Disease: Part V -- Statins Versus Aspirin for Primary Prevention, And the Winner Is...? Moyad, Mark A.; Merrick, Gregory S. // Urologic Nursing;Apr2007, Vol. 27 Issue 2, p166 

    The article reports on the plan of Pfizer Inc. to stop the clinical trial for the High-Density Lipoprotein (HDL) boosting drug torceptrapib and the natural methods that can increase HDL levels. Pfizer stopped the Phase III clinical trial of the drug for it is found to cause life-threatening side...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics